Lineage Cell Therapeutics (LCTX) Other financing activities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Other financing activities of $227000.0 for Q1 2026, down 70.25% quarter-over-quarter from $763000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other financing activities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $227000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $227000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 1422.68% YoY), while the FY2025 annual figure was $1.2 million, up 445.85% from the prior year.
- Other financing activities for Q1 2026 stood at $227000.0, down from $763000.0 in the prior quarter.
- The five-year high for Other financing activities was $892000.0 in Q3 2022, with the low at -$343000.0 in Q4 2022.
- The 5-year median for Other financing activities is $87000.0 (2024), against an average of $187846.2.
- The sharpest annual moves came in 2022 and 2025: Other financing activities plunged 135.32% in 2022, then soared 4770.0% in 2025.
- Lineage Cell Therapeutics' Other financing activities stood at -$343000.0 in 2022, then soared by 102.33% to $8000.0 in 2023, then climbed by 25.0% to $10000.0 in 2024, then jumped by 7530.0% to $763000.0 in 2025, then plunged by 70.25% to $227000.0 in 2026.
- Business Quant data shows LCTX's Other financing activities at $227000.0 in Q1 2026, $763000.0 in Q4 2025, and $487000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 763,000.00 |
| Dec 31, 2025 | 763,000.00 |
| Sep 30, 2025 | 487,000.00 |
| Sep 30, 2025 | 487,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 29,000.00 |
| Jun 30, 2023 | 29,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | -343,000.00 |
| Dec 31, 2022 | -343,000.00 |